

AD_____

Award Number: W81XWH-11-1-0446

TITLE: Treatment of Multiple Myeloma with VLA4-targeted Nanoparticles Delivering Novel c-MYC Inhibitor Prodrug

PRINCIPAL INVESTIGATOR: Michael Tomasson

CONTRACTING ORGANIZATION: Washington University
St Louis, MO 63130

REPORT DATE: September 2012

TYPE OF REPORT: Revised Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE September 2012		2. REPORT TYPE Revised Annual		3. DATES COVERED 1 September 2011-31 August 2012	
4. TITLE AND SUBTITLE Treatment of Multiple Myeloma with VLA4-targeted Nanoparticles Delivering Novel c-MYC Inhibitor Prodrug				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-11-1-0446	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Michael Tomasson				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Washington University St Louis, MO 63130				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Rationale: Multiple myeloma (MM) is an incurable malignancy derived from antibody secreting B lineage plasma cells. MM is the second most common malignancy in the United States and accounts for 1% of cancer deaths. Despite recent advances, the 5-year survival rate in patients with MM is less than 40% MM responds well to chemotherapy and remissions occur in that majority of MM patients, but all patients eventually relapse and die from progressive disease within 6 years. If the residual post-remission cells of their activation to progressive disease could be disrupted with novel targeted therapies. It would have a significant impact on the care and treatment of MM patients, particularly male veterans who are at 51% increased risk of MM compared to general public.					
15. SUBJECT TERMS- none provide					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction	2-3
2. Keywords	4
3. Overall Project Summary	5-7
4. Key Research Accomplishments	8
5. Conclusion	9
6. Publications, Abstracts, and Presentations	10
7. Inventions, Patents and Licenses	11
8. Reportable Outcomes	12-14
9. Other Achievements	15
10. References	16-18
11. Appendices	18

1. Introduction:

Multiple myeloma is the second most common hematological cancer in the world. It is characterized by accumulation of malignant plasma cells in the bone marrow, osteolytic lesions and monoclonal immunoglobulins in blood and/or urine (Antonio, 2011). While understanding of the mechanisms of drug resistance in MM is limited, interactions with the bone marrow microenvironment are a major contributing factor (Masahiro A, 2011). Thus, novel agents targeting the tumor vasculature and microenvironment are needed. One approach is to exploit the membrane glycoproteins including integrins that mediate stromal interactions. Integrins are heterodimer adhesive receptors expressed by virtually all cell types, including cancer cells (Hynes, 2002; Desgrosellier JS 2010). Several integrins are expressed by MM cells, predominantly the $\alpha 4$, $\alpha 5$, αv and the $\beta 1$ subunits. The $\alpha 4\beta 1$ integrin (CD49d or VLA-4) is expressed by both normal and malignant plasma cells (Pals ST, 2007) and is over-expressed in drug-resistant MM cells (Damiano JS, 2010). Integrins are critical to tumor angiogenesis, cell adhesion, and migration (Ruoslahti *et al.*, 1996). Adherent integrin-stromal interactions also enhances the proliferation of MM cells (Ria, R, 2002.). MM still remains an incurable disease and disease relapse occur in the vast majority of MM patients.

Myc genes encode basic helix–loop–helix–leucine zipper (bHLHZip) transcription factors that heterodimerize with their partner protein Max to bind DNA, regulate target gene expression, and modulate numerous biological functions (Amati *et al.*, 1993; Crouch *et al.*, 1990, 1993; Evan *et al.*, 1992; Freytag *et al.*, 1990; Smith *et al.*, 1990). The Myc pathway plays a central role in the evolution of MGUS into MM (Anguiano A, 2009). [ALSO PLEASE SEE/CITE: <http://www.jci.org/articles/view/61188> and PMID 22806891] The c-Myc protein is up-regulated in a large fraction of human cancers yet

remains a challenging target for drug discovery (Hermeking, H. 2003, Prochownik, E. V 2004, Darnell, J. E 2002, Gibbs, J. B. 2000). Several small-molecule inhibitors of the c-Myc-Max interaction have been reported (Kiessling, A 2006, Mo, H.; Henriksson, 2006, Xu, Y 2006, Berg, T 2002, Bagnasco, L 2007, Pescarolo, M. P 2001, Yin, X. 2003), but none have yet been validated in clinical trials. Max inhibitors could be explored for their therapeutic potentials for various diseases overexpressing Myc including cancers such as multiple myeloma (Toril H, 2012).

Nanoparticles are promising carriers for anticancer agents that allow for selective drug delivery and increased drug levels at target sites. (Temming, Kai, 2005), Here, we investigated the effects of integrin-targeted nanoparticles as Myc drug delivery vehicles to MM cells. The selectivity of these targeted NPs was achieved by exploiting the presence of the Integrins $\alpha_v\beta_3$ and $\alpha_4\beta_1$, which are known to be linked to both tumor angiogenesis and metastasis in MM cells.

2. Keywords: Myeloma, Cancer, Nanoparticles, Nanotechnology

3. Overall Project Summary:

Myc Drug and Prodrug are cytotoxic for MM cells: The effects on the cellular growth and viability were determined using murine and human MM cell lines. A significant decrease in cell viability was observed following treatment with the Myc Prodrug in comparison to the myc drug at equimolar concentrations in all MM cells lines at 24 Hrs (**Figure 2 A**). The results were confirmed by PE Annexin V staining. 92%, 91% and 92% of cells treated with Prodrug for 24 hrs were observed to be PE Annexin V positive, suggesting that they were in end stage apoptosis or already dead (**Figure 2B**), compared to 19%, 31% and 31% treated with the Myc drug in H929, U266 and 5TGM1 cells respectively . Increased cytotoxicity observed with prodrug versus base compound was expected due to increased hydrophobicity caused by addition of hydrocarbon tail. We developed nanoparticle envelopes to target the Myc prodrug because this hydrophobic compound would not be workable for animal or human studies.

Expression levels of Integrins $\alpha v \beta 3$ and $\alpha 4 \beta 1$ on MM cells: To determine whether the target (Integrin $\alpha v \beta 3$ and $\alpha 4 \beta 1$) specific delivery of the Prodrug within the NPs is correlated with quantitative changes in expression of nanoparticle integrin targets, we examined integrin subunit ($\alpha 4$ and αv) expression in human and mouse MM cell lines using immunoblots. Integrin αv was expressed only in H929 and U-266 cells at protein levels (**Figure 3A**) whereas Integrin $\alpha 4$ was abundantly expressed in the all the MM cell lines used (**Figure 4A**). Manganese (Mn^{2+}) treatment induces "inside-out" signaling and conformational activation of integrin receptors which significantly changes epitope availability (Hu P, 2012). Expression of Integrin $\alpha v \beta 3$ on cells was also determined using flow cytometry with a species-specific antibody for both Mn activated and non-

activated human MM cell lines. Interestingly, only the cell lines expressing the protein for Integrin αv (**Figure 3A**) (H929 and U-266) showed almost 40% of cells (**Figure 3B**).

Specificity of integrin targeting of nanoparticles to MM cells correlates with target expression. To verify that the specificity and binding of these nanoparticles to the cells depends upon the expression levels of the integrins, human H929 and U-266 cells expressing high levels of both the Integrins, $\alpha v\beta 3$ and $\alpha 4\beta 1$ were used. These MM cells were then treated Rhodamine Labeled Integrin Targeted (Integrin $\alpha v\beta 3$ and $\alpha 4\beta 1$) and non-Targeted Nanoparticles. As postulated, the Integrin expressing cells bound to Integrin targeted NP with higher affinity than the non-targeted counterparts, with the integrin $\alpha v\beta 3$ Tg NP labeling 64% (H929) and 54% (U266) cells and Integrin $\alpha 4\beta 1$ Tg NP labeling 65.9% (H929) and 65.5 (U266) cells. (**Figure 3C & 4B**). We next sought to determine whether the 5TGM1 murine cell line expressed these integrins, and we found 5TGM1 highly expressed Integrin $\alpha 4$ (89%) (**Figure 4D**) and very low levels of integrin αv (8.1%) (**Figure 3D**), which was further confirmed by binding of rhodamine-labeled counterparts of $\alpha 4\beta 1$ targeted NPs to these cells (**Figure 4C**).

$\alpha 4\beta 1$ targeted-NPs are cytotoxic for myeloma cell lines

We evaluated the cytotoxicity of the integrin-targeted NPs on myeloma cell lines. Integrin $\alpha v\beta 3$ Tg NPs weakly inhibited the growth of KMS-11 and 5TGM1, which was expected as integrin $\alpha v\beta 3$ was not present at significant levels in both the cell lines (**Figure 5C & D**). In contrast, Tg (Integrin $\alpha v\beta 3$ and $\alpha 4\beta 1$) NPs significantly inhibited the growth of high-expressing U266 and H929 cell lines at equimolar concentrations (**Figure 5A & B**). Together, these data demonstrate that the integrin-Tg NP specifically

inhibited the growth of myeloma cell lines in relation to the expression levels of the target integrin on the surface of the myeloma cells. Control experiments performed with media, DMSO and Myc Drug yielded very similar results to those obtained with non-targeted NPs. Whereas, the efficacy of the myc prodrug in cell killing was significantly higher in all the cell lines irrespective of the Integrin expression levels. Therefore, using Tg NPs for the delivery of this prodrug showed cytotoxic effects with higher specificity depending on the Integrin expression of the cell line used.

4. Key Research Accomplishments:

1. We obtained approval including the local IACUC and DoD Office of Research Protection approval.
2. We performed in vivo efficacy studies of VLA-targeted Sn-2 Myc-inhibitor nanoparticles in mouse models of MM. We have collected blood and tissue for assays to correlate with overall visceral and bone tumor burden and estimate osteoclast and osteoblast activity and tumor burden.
3. We performed quantitative flow cytometry and histological assessments of bone marrow multiple myeloma tumor cell burden and collateral marrow hematopoietic and stromal populations in response to VLA- targeted Sn-2 Myc-inhibitor nanoparticles.

5. Conclusion:

We have completed initial testing of VLA-4-targeted, anti-Myc nanoparticles and have found specific and significant effects using myeloma cell lines. We are now proceeding to the characterization of these nanoparticles in pre-clinical mouse models of myeloma that we have "up and running" in the laboratory. We are currently investigating the effects of anti-Myc nanoparticles on tumor cells and normal tissues of mice.

6. Publications, Abstracts, and Presentations:

None

7. Inventions, Patents and Licenses:

None

8. Reportable Outcomes:

Figure 1




Figure 2




Figure 3





Figure 4



9. Other Achievements:

None

10. References:

1. Murre, C., McCaw, P.S., Vaessin, H., Caudy, M., Jan, L.Y., Jan, Y.N., Cabrera, C.V., Buskin, J.N., Hauschka, S.D., Lassar, A.B., et al. Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. *Cell*. 1989; 58(3):537-544.
2. Dang, C.V., McGuire, M., Buckmire, M., and Lee, W.M. Involvement of the 'leucine zipper' region in the oligomerization and transforming activity of human c-myc protein. *Nature*. 1989; 337(6208):664-666.
3. Amati, B., Brooks, M.W., Levy, N., Littlewood, T.D., Evan, G.I., and Land, H. Oncogenic activity of the c-Myc protein requires dimerization with Max. *Cell*. 1993; 72(2):233-245.
4. Crouch, D.H., Lang, C., and Gillespie, D.A. The leucine zipper domain of avian cMyc is required for transformation and autoregulation. *Oncogene*. 1990; 5(5):683-689.
5. Evan, G.I., Wyllie, A.H., Gilbert, C.S., Littlewood, T.D., Land, H., Brooks, M., Waters, C.M., Penn, L.Z., and Hancock, D.C. Induction of apoptosis in fibroblasts by c-myc protein. *Cell*. 1992; 69(1):119-128.
6. Freytag, S.O., Dang, C.V., and Lee, W.M. Definition of the activities and properties of c-myc required to inhibit cell differentiation. *Cell Growth Differ*. 1990; 1(7):339-343.
7. Smith, M.J., Charron-Prochownik, D.C., and Prochownik, E.V. The leucine zipper of c-Myc is required for full inhibition of erythroleukemia differentiation. *Mol Cell Biol*. 1990; 10(10):5333-5339.
8. Darnell, J.E., Jr. Transcription factors as targets for cancer therapy. *Nat Rev Cancer*. 2002; 2(10):740-749.
9. Gibbs, J.B. Mechanism-based target identification and drug discovery in cancer research. *Science*. 2000; 287(5460):1969-1973.
10. Hermeking, H. The MYC oncogene as a cancer drug target. *Curr Cancer Drug Targets*. 2003; 3(3):163-175.

11. Prochownik, E.V. c-Myc as a therapeutic target in cancer. *Expert Rev Anticancer Ther.* 2004; 4(2):289-302.
12. Yin, X., Giap, C., Lazo, J.S., and Prochownik, E.V. Low molecular weight inhibitors of Myc-Max interaction and function. *Oncogene.* 2003; 22(40):6151-6159.
13. Xu, Y., Shi, J., Yamamoto, N., Moss, J.A., Vogt, P.K., and Janda, K.D. A credit-card library approach for disrupting protein-protein interactions. *Bioorg Med Chem.* 2006; 14(8):2660-2673.
14. Pescarolo, M.P., Bagnasco, L., Malacarne, D., Melchiori, A., Valente, P., Millo, E., Bruno, S., Basso, S., and Parodi, S. A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems. *FASEB J.* 2001; 15(1):31-33.
15. Mo, H., and Henriksson, M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. *Proc Natl Acad Sci U S A.* 2006; 103(16):6344-6349.
16. Kiessling, A., Sperl, B., Hollis, A., Eick, D., and Berg, T. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. *Chem Biol.* 2006; 13(7):745-751.
17. Berg, T., Cohen, S.B., Desharnais, J., Sonderegger, C., Maslyar, D.J., Goldberg, J., Boger, D.L., and Vogt, P.K. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. *Proc Natl Acad Sci U S A.* 2002; 99(6):3830-3835.
18. Bagnasco, L., Tortolina, L., Biasotti, B., Castagnino, N., Ponassi, R., Tomati, V., Nieddu, E., Stier, G., Malacarne, D., and Parodi, S. Inhibition of a protein-protein interaction between INI1 and c-Myc by small peptidomimetic molecules inspired by Helix-1 of c-Myc: identification of a new target of potential antineoplastic interest. *FASEB J.* 2007; 21(4):1256-1263.
19. Holien, T., Vatsveen, T.K., Hella, H., Waage, A., and Sundan, A. Addiction to c-MYC in multiple myeloma. *Blood.* 2012; 120(12):2450-2453.

20. Palumbo, A., and Anderson, K. Multiple myeloma. *N Engl J Med.* 2011; 364(11):1046-1060.
21. Desgrosellier, J.S., and Cheresch, D.A. Integrins in cancer: biological implications and therapeutic opportunities. *Nat Rev Cancer.* 2010; 10(1):9-22.
22. Hynes, R.O. Integrins: bidirectional, allosteric signaling machines. *Cell.* 2002; 110(6):673-687.
23. Pals, S.T., de Gorter, D.J., and Spaargaren, M. Lymphoma dissemination: the other face of lymphocyte homing. *Blood.* 2007; 110(9):3102-3111.
24. Damiano, J.S., and Dalton, W.S. Integrin-mediated drug resistance in multiple myeloma. *Leuk Lymphoma.* 2000; 38(1-2):71-81.
25. Ruoslahti, E. RGD and other recognition sequences for integrins. *Annu Rev Cell Dev Biol.* 1996; 12:697-715.
26. Ria, R., Vacca, A., Ribatti, D., Di Raimondo, F., Merchionne, F., and Dammacco, F. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. *Haematologica.* 2002; 87(8):836-845.
27. Temming, K., Schiffelers, R.M., Molema, G., and Kok, R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. *Drug Resist Updat.* 2005; 8(6):381-402.

Appendices: None